Authorized purpose: Post-processing image analysis to assist clinicians in viewing, analyzing, and evaluating MR brain images through automated segmentation, quantitative analysis, normative comparison, and report presentation.
Clinical role
Post-acquisition automated brain-structure and white-matter-hyperintensity segmentation, volumetry, normative comparison, and longitudinal follow-up, with confirmation or decline of results before sending them to PACS.
Images and patients
MRI · Brain structures and white matter hyperintensities
Key limitation
Keep in mind: Inputs exclude non-T1 MPRAGE, non-T2 3D FLAIR, contrast-enhanced T1 MPRAGE, and derived images. The packet states testing on Microsoft Windows 10 and no validation on other operating systems, Mac, touch screens, or mobile devices. WMH follow-up testing used 75 Siemens 3.0T subjects with MS or Alzheimer disease; morphometry follow-up had verification and validation but no additional scientific evaluation in the submission.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Post-processing image analysis to assist clinicians in viewing, analyzing, and evaluating MR brain images through automated segmentation, quantitative analysis, normative comparison, and report presentation.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain structures and white matter hyperintensities Input: T1-weighted MPRAGE series for morphometry; T1-weighted MPRAGE and T2-weighted 3D FLAIR series for white-matter-hyperintensity analysis; follow-up uses two MPRAGE scans from the same patient at two time points and paired datasets for white-matter-hyperintensity changes.
Who uses it?Intended users: Clinicians and healthcare professionals familiar with post-processing MR images, including radiologists.
What does the software produce?Output: Absolute and normalized brain-structure volumes, age-matched normative deviations, 3D label/deviation overlays and out-of-range flags, white-matter-hyperintensity count and volume across four regions, and follow-up atrophy rates plus new/enlarged lesion maps, counts, and volumes, with DICOM SR/SC/PDF reporting to PACS.
What is its most important limitation?Key limitation: Inputs exclude non-T1 MPRAGE, non-T2 3D FLAIR, contrast-enhanced T1 MPRAGE, and derived images. The packet states testing on Microsoft Windows 10 and no validation on other operating systems, Mac, touch screens, or mobile devices. WMH follow-up testing used 75 Siemens 3.0T subjects with MS or Alzheimer disease; morphometry follow-up had verification and validation but no additional scientific evaluation in the submission.
Clinical takeaway. Clinical role: Post-processing image analysis to assist clinicians in viewing, analyzing, and evaluating MR brain images through automated segmentation, quantitative analysis, normative comparison, and report presentation.
Evidence takeaway. Evidence from the reviewed source record: FDA nonclinical verification and validation covered the product updates; the submission states no clinical tests were conducted because the predicate was not clinically validated. Scientific evaluation of the WMH follow-up feature used 75 subjects and 150 studies, with three manual ground-truth annotations per dataset. Acceptance criteria were PCC >=0.77 for volumetric segmentation, mean Dice >=0.47 for voxel-wise segmentation, and median F1 >=0.69 for WMH change-region segmentation. Reported averages were PCC 0.94 (95% CI 0.83-0.98), Dice 0.50 (0.42-0.57), and F1 0.69 (0.633-0.733). These are PCC, Dice, and lesion-wise F1 endpoints, not sensitivity or specificity.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Post-processing image analysis to assist clinicians in viewing, analyzing, and evaluating MR brain images through automated segmentation, quantitative analysis, normative comparison, and report presentation.
Post-acquisition automated brain-structure and white-matter-hyperintensity segmentation, volumetry, normative comparison, and longitudinal follow-up, with confirmation or decline of results before sending them to PACS.
T1-weighted MPRAGE series for morphometry; T1-weighted MPRAGE and T2-weighted 3D FLAIR series for white-matter-hyperintensity analysis; follow-up uses two MPRAGE scans from the same patient at two time points and paired datasets for white-matter-hyperintensity changes.
Absolute and normalized brain-structure volumes, age-matched normative deviations, 3D label/deviation overlays and out-of-range flags, white-matter-hyperintensity count and volume across four regions, and follow-up atrophy rates plus new/enlarged lesion maps, counts, and volumes, with DICOM SR/SC/PDF reporting to PACS.
Clinical brain-MR post-processing workflow; the FDA comparison describes cloud-based or on-edge deployment in the institution premise but does not specify a facility type.
Inputs exclude non-T1 MPRAGE, non-T2 3D FLAIR, contrast-enhanced T1 MPRAGE, and derived images. The packet states testing on Microsoft Windows 10 and no validation on other operating systems, Mac, touch screens, or mobile devices. WMH follow-up testing used 75 Siemens 3.0T subjects with MS or Alzheimer disease; morphometry follow-up had verification and validation but no additional scientific evaluation in the submission.
FDA nonclinical verification and validation covered the product updates; the submission states no clinical tests were conducted because the predicate was not clinically validated. Scientific evaluation of the WMH follow-up feature used 75 subjects and 150 studies, with three manual ground-truth annotations per dataset. Acceptance criteria were PCC >=0.77 for volumetric segmentation, mean Dice >=0.47 for voxel-wise segmentation, and median F1 >=0.69 for WMH change-region segmentation. Reported averages were PCC 0.94 (95% CI 0.83-0.98), Dice 0.50 (0.42-0.57), and F1 0.69 (0.633-0.733). These are PCC, Dice, and lesion-wise F1 endpoints, not sensitivity or specificity.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA nonclinical verification and validation covered the product updates; the submission states no clinical tests were conducted because the predicate was not clinically validated. Scientific evaluation of the WMH follow-up feature used 75 subjects and 150 studies, with three manual ground-truth annotations per dataset. Acceptance criteria were PCC >=0.77 for volumetric segmentation, mean Dice >=0.47 for voxel-wise segmentation, and median F1 >=0.69 for WMH change-region segmentation. Reported averages were PCC 0.94 (95% CI 0.83-0.98), Dice 0.50 (0.42-0.57), and F1 0.69 (0.633-0.733). These are PCC, Dice, and lesion-wise F1 endpoints, not sensitivity or specificity.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
AI-Rad Companion Brain MR regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionVA50C
Samplen=1289
IndependenceIndependence not established
K232305
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K232305. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: T1-weighted MPRAGE series for morphometry; T1-weighted MPRAGE and T2-weighted 3D FLAIR series for white-matter-hyperintensity analysis; follow-up uses two MPRAGE scans from the same patient at two time points and paired datasets for white-matter-hyperintensity changes.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA packet describes PACS using DICOM-compatible communication, AI-Rad Companion Engine/Notifier workflow, confirmation before sending results, and DICOM SR, DICOM SC, and PDF outputs. It describes cloud-based or on-edge institutional architecture, Windows 10 and a recommended Chrome browser, but does not establish local interface versions or compatibility.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes cloud-based and on-edge deployment in the institution premise; for edge deployment, data processing is performed within the institution, while logging, institution management, and audit logging are performed in the cloud. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Architecture Cloud-based and on- Cloud-based and on- Cloud only solution edge deployment in the edge deployment in the with no components institution premise." … "Edge deployment, the Edge deployment, the customer premise. data processing is data processing is performed within the performed within the institution whereas". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Absolute and normalized brain-structure volumes, age-matched normative deviations, 3D label/deviation overlays and out-of-range flags, white-matter-hyperintensity count and volume across four regions, and follow-up atrophy rates plus new/enlarged lesion maps, counts, and volumes, with DICOM SR/SC/PDF reporting to PACS.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Absolute and normalized brain-structure volumes, age-matched normative deviations, 3D label/deviation overlays and out-of-range flags, white-matter-hyperintensity count and volume across four regions, and follow-up atrophy rates plus new/enlarged lesion maps, counts, and volumes, with DICOM SR/SC/PDF reporting to PACS.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes cloud-based and on-edge deployment in the institution premise; for edge deployment, data processing is performed within the institution, while logging, institution management, and audit logging are performed in the cloud. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Architecture Cloud-based and on- Cloud-based and on- Cloud only solution edge deployment in the edge deployment in the with no components institution premise." … "Edge deployment, the Edge deployment, the customer premise. data processing is data processing is performed within the performed within the institution whereas". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The FDA packet describes PACS using DICOM-compatible communication, AI-Rad Companion Engine/Notifier workflow, confirmation before sending results, and DICOM SR, DICOM SC, and PDF outputs. It describes cloud-based or on-edge institutional architecture, Windows 10 and a recommended Chrome browser, but does not establish local interface versions or compatibility.
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.
Siemens Healthineers' cybersecurity page states that its Cybersecurity Management Service maintains a product security inventory of over 1,000 product versions and over 21,000 monitored software components, with security whitepapers, SBOMs and vulnerability assessments delivered via teamplay Fleet, and that it operates incident and vulnerability management.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names Siemens Healthineers generally and does not scope these commitments to any specific product release; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for AI-Rad Companion Brain MR; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
9Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K232305 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: Automatic labeling, visualization, and volumetric quantification of segmentable brain structures from MR images, with complementary segmentations, visualizations, and volume measurements for trained professionals evaluating MR brain images and preparing quantitative reports.
Modality
MRI
Anatomy
Brain structures and white matter hyperintensities
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Authorized purpose: Neurophet AQUA is intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from a set of MR images; volumetric data may be compared to reference percentile data.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.